RRML - Clinical applications of total PSA and free PSA tumor markers

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2016): 55%

Clarivate analytics (ISI) Impact factor

Top 10 downloaded articles - July 2020 -

Multiplex ligation-dependent p...	3
Undetectable hemoglobin in a p...	2
Implications of visfatin genet...	2
Antimicrobial activity of diff...	2
The predictive role of platele...	2
Genetic variability of ANG2 -3...	2
Validation of GOD / PAP method...	1
A model for calculating measur...	1
Bioanalytical method validatio...	1
Genetic Polymorphism of DNA re...	1

Concept, Design & Programming
Dr. Adrian Man

Nr. 1(1)/2005

Clinical applications of total PSA and free PSA tumor markers

Adina Elena Stanciu

Abstract:

During the last 10 years the most widely used tumor marker for early detection of the prostate cancer was the prostate specific antigen (PSA). The concentration of total PSA in serum correlates with the volume of prostate cancer and changes in the levels reflect the disease process. It’s a very good relationship between serum total PSA, tumor size and stage of the disease. Total PSA is a sensitive serum marker for prostate cancer, but its specificity is limited by a high frequency of falsely elevated values in men with benign prostatic hyperplasia (BPH). Therefore, the determination of the proportion of the free PSA has become widely used to improve the can-cer specificity of total PSA, especially in men with PSA values in the “grey zone” (4-10 ng/ml). Free PSA values can help differentiate prostate cancer from BPH and reduce the number of unnecessary biopsies.

Keywords: total PSA,free PSA,prostate cancer,benign prostatic hyperplasia

Download full text PDF
(325 KB)

Stanciu AE. Clinical applications of total PSA and free PSA tumor markers . Rev Romana Med Lab. 2005;1(1):33-7